Acute Kidney Injury News

An analysis of patients who were hospitalized with COVID-19 in Belgium demonstrated SARS-CoV-2 caused specific manifestations of kidney proximal tubule dysfunction.

With many patients avoiding in-office visits due to COVID-19 concerns, self-management in lupus is more important than ever, according to a presenter at the 2020 Rheumatology Nurses Society Annual Conference.

Initiating dialysis within 12 hours of developing AKI, deemed the “accelerated” approach, was not associated with lower mortality risk compared with starting therapy after 72 hours, according to study results.

Biopsies performed in patients who developed AKI after being diagnosed with COVID-19 showed no viral presence of SARS-CoV-2 in the kidneys, according to a recently published study.

FDA Cardiovascular and Renal Drugs Advisory Committee voted 8-7 to recommend approval of terlipressin for the treatment of hepatorenal syndrome type 1 in patients with cirrhosis.

Patients who developed kidney failure due to AKI had a higher risk for mortality than those who developed the condition from diabetes or other causes, according to study results.

Researchers successfully integrated a risk algorithm into the electronic health record at an urban, tertiary-care hospital. The algorithm accurately predicted which patients would go on to develop AKI within 24 hours.

Use of low-sodium dialysate and replacement fluids safely prevented an “overly rapid” correction of plasma sodium in a study of patients with hyponatremia who required continuous renal replacement therapy.

Newly published research from the United Kingdom demonstrates terlipressin is effective for improving kidney function in hospitalized patients with hepatorenal syndrome type 1.

A study of patients admitted to New York hospitals with COVID-19 found acute kidney injury was common. Findings also suggested AKI developed in early stages of the disease and in conjunction with respiratory failure.